Login to Your Account



Allozyne Inks Reverse Merger with Cash-Strapped Poniard

By Jennifer Boggs


Friday, June 24, 2011
Reverse mergers, which had dropped in status as the initial public offering (IPO) window creaked open for biotechs in the past year, look to be making a comeback, if the recent spate of deals is any indication. The latest deal has private firm Allozyne Inc. merging with struggling public biotech Poniard Pharmaceuticals Inc. in a stock-for-stock transaction.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription